Cancer Therapy-related Cardiac Dysfunction Occuring in Children Treated by Anticancer Drugs for Malignancies
NCT ID: NCT05602103
Last Updated: 2024-05-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
10000 participants
OBSERVATIONAL
2024-11-05
2025-01-06
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Epidemiology of Cardiotoxicity in Children With Cancer
NCT00005418
Evaluation of Cardiac and Endothelial Function in Children and Adolescents Treated With Anthracycline
NCT07253077
Preventing Cardiac Sequelae in Pediatric Cancer Survivors
NCT01805778
Pharmacogenetic Study of Antimitotic Therapies Involved in Hepatic VOD in Children With Nephroblastoma or ALL
NCT04168788
Evaluating the Side Effects and How Well Anticancer Drugs Work in Very Young Patients With Cancer
NCT00897871
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
RETROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
use of anticancer drugs in monotherapy or in combination therapy
Cases of cancer therapy-related cardiac dysfunction associated with anticancer drugs will be identify and describe
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* related to children
* and reported, or not, cancer therapy-related cardiac dysfunction
Exclusion Criteria
0 Years
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Caen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Joachim Alexandre, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Caen Normandy University Hospital, France
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Pharmaco_112022
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.